STOCK TITAN

First Wave BioPharma Inc - FWBI STOCK NEWS

Welcome to our dedicated news page for First Wave BioPharma (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect First Wave BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of First Wave BioPharma's position in the market.

News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.14%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
clinical trial
Rhea-AI Summary
First Wave BioPharma, Inc. will participate in the EF Hutton Inaugural Global Conference on May 10-11, 2023. The company's management team will conduct meetings with investors and pharmaceutical companies to discuss their business strategy, recent achievements, and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.76%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.48%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
clinical trial
First Wave BioPharma Inc

Nasdaq:FWBI

FWBI Rankings

FWBI Stock Data

7.80M
648.59k
6.94%
4.18%
1.94%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Brooklyn

About FWBI

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.